Baltimore biotech star aims to detect cancer mutations early
Courtesy of I. Kinde
Isaac Kinde, 31
Papgene, Inc. | Biotechnology
Graduate school: Johns Hopkins
Isaac Kinde became interested in medicine in elementary school. On Sundays, his father, a large-animal veterinarian, brought Isaac to work. “Seeing what disease could do to animals got me interested, piqued my curiosity,” Kinde says.
Kinde is chief scientific officer at PapGene, a small biotechnology startup in Baltimore founded in 2014. The company is producing advanced technologies to detect cancer before a tumor can cause symptoms or be picked up by an imaging scan. Kinde’s work is inspired by a simple idea: Cancers are much easier to treat when detected early. And that can translate into fewer deaths.
PapGene’s technologies identify mutated genes associated with cancer in a Pap